본 증례는 다발성 골수종을 진단 후 Bortezomib, Melphalan, Prednisolone 항암치료 중에 급성 췌장염이 발생된 매우 드문 경우이다. 급성 췌장염이 원인을 알기 위하여 알코올 병력, 담석증, 외상, 고칼슘혈증, 고중성지방혈증 등에 대한 혈액검사 및 영상의학적 검사를 시행하였지만 특별한 소견은 없었다. 급성 췌장염을 유발할 수 있는 약제인 Bortezomib이 그 원인일 가능성으로 판단되어 Bortezomib 중단과 보존적 치료로 급성 췌장염이 호전되었다. Bortezomib은 다 양한 비특이적인 위장관 증상을 흔하게 유발할 수 있지만 복통이 지속되거나 재발하면 드물지만 급성 췌장염이 발생할 수 있음을 염두에 두어야 하겠다.

(‐)‐Epigallocatechin 3‐gallate (EGCG) is a potent antioxidant polyphenol in green tea that acts as an anticancer agent via both direct and indirect pathways. Although the relationship between EGCG’s anticancer effects and its antioxidant activity is not fully understood, it is known that EGCG stimulates production of reactive oxygen species (ROS), which induce oxidative stress leading to cell death. In IM9 multiple myeloma cells, EGCG acted in a dose‐ and time‐dependent manner to induce apoptotic cell death. Among the antioxidant enzymes expressed in IM9 cells, levels of peroxiredoxin (Prdx) V were selectively and significantly reduced by EGCG. Moreover, the ROS scavenger NAC completely inhibited EGCG‐induced apoptosis and PrdxV reduction, while overexpression of PrdxV, but not a PrdxVC48S mutant, protected IM9 cells from EGCG‐induced apoptosis. EGCG‐induced reductions in cell viability and PrdxV levels were also observed in primary CD138+ multiple myeloma cells from patients. These results suggest that PrdxV is a key target via which EGCG mediates its anticancer effects.